Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study.
<h4>Background</h4>The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/edb9fbd2367a41d599df991edc0a382c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:edb9fbd2367a41d599df991edc0a382c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:edb9fbd2367a41d599df991edc0a382c2021-11-18T05:42:06ZReduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study.1549-12771549-167610.1371/journal.pmed.1001305https://doaj.org/article/edb9fbd2367a41d599df991edc0a382c2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22973182/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects against P. vivax infection and disease.<h4>Methods and findings</h4>The association between SAO and P. vivax infection was examined through genotyping of 1,975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence rate ratio [IRR] = 0.54, 95% CI 0.40-0.72, p<0.0001) in a cohort of infants aged 3-21 months and a significant 52% reduction in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22-71, p = 0.003) and 55% by light microscopy (95% CI 13-77, p = 0.014), respectively, in a cohort of children aged 5-14 years. SAO was also associated with a reduction in risk of P. vivax parasitaemia in children 3-21 months (1,111/µl versus 636/µl, p = 0.011) and prevalence of P. vivax infections in children 15-21 months (odds ratio [OR] = 0.39, 95% CI 0.23-0.67, p = 0.001). In a case-control study of children aged 0.5-10 years, no child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR = 0, 95% CI 0-1.56, p = 0.11). SAO was associated with protection against severe P. falciparum malaria (OR = 0.38, 95% CI 0.15-0.87, p = 0.014) but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum. Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO children, high level (>90% binding inhibition) P. vivax Duffy binding protein-specific binding inhibitory antibodies were observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p = 0.008).<h4>Conclusions</h4>In three independent studies, we observed strong associations between SAO and protection against P. vivax malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the unique host genetic adaptations to malaria in Asian and Oceanic populations. Please see later in the article for the Editors' Summary.Anna Rosanas-UrgellEnmoore LinLaurens ManningPatricia RarauMoses LamanNicolas SennBrian T GrimbergLivingstone TavulDanielle I StanisicLeanne J RobinsonJohn J AponteElijah DabodJohn C ReederPeter SibaPeter A ZimmermanTimothy M E DavisChristopher L KingPascal MichonIvo MuellerPublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 9, Iss 9, p e1001305 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R |
| spellingShingle |
Medicine R Anna Rosanas-Urgell Enmoore Lin Laurens Manning Patricia Rarau Moses Laman Nicolas Senn Brian T Grimberg Livingstone Tavul Danielle I Stanisic Leanne J Robinson John J Aponte Elijah Dabod John C Reeder Peter Siba Peter A Zimmerman Timothy M E Davis Christopher L King Pascal Michon Ivo Mueller Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| description |
<h4>Background</h4>The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion in the erythrocyte band 3 gene, SLC4A1Δ27) protects against cerebral malaria caused by Plasmodium falciparum; however, it is unknown whether this polymorphism also protects against P. vivax infection and disease.<h4>Methods and findings</h4>The association between SAO and P. vivax infection was examined through genotyping of 1,975 children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence rate ratio [IRR] = 0.54, 95% CI 0.40-0.72, p<0.0001) in a cohort of infants aged 3-21 months and a significant 52% reduction in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22-71, p = 0.003) and 55% by light microscopy (95% CI 13-77, p = 0.014), respectively, in a cohort of children aged 5-14 years. SAO was also associated with a reduction in risk of P. vivax parasitaemia in children 3-21 months (1,111/µl versus 636/µl, p = 0.011) and prevalence of P. vivax infections in children 15-21 months (odds ratio [OR] = 0.39, 95% CI 0.23-0.67, p = 0.001). In a case-control study of children aged 0.5-10 years, no child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR = 0, 95% CI 0-1.56, p = 0.11). SAO was associated with protection against severe P. falciparum malaria (OR = 0.38, 95% CI 0.15-0.87, p = 0.014) but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum. Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO children, high level (>90% binding inhibition) P. vivax Duffy binding protein-specific binding inhibitory antibodies were observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p = 0.008).<h4>Conclusions</h4>In three independent studies, we observed strong associations between SAO and protection against P. vivax malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the unique host genetic adaptations to malaria in Asian and Oceanic populations. Please see later in the article for the Editors' Summary. |
| format |
article |
| author |
Anna Rosanas-Urgell Enmoore Lin Laurens Manning Patricia Rarau Moses Laman Nicolas Senn Brian T Grimberg Livingstone Tavul Danielle I Stanisic Leanne J Robinson John J Aponte Elijah Dabod John C Reeder Peter Siba Peter A Zimmerman Timothy M E Davis Christopher L King Pascal Michon Ivo Mueller |
| author_facet |
Anna Rosanas-Urgell Enmoore Lin Laurens Manning Patricia Rarau Moses Laman Nicolas Senn Brian T Grimberg Livingstone Tavul Danielle I Stanisic Leanne J Robinson John J Aponte Elijah Dabod John C Reeder Peter Siba Peter A Zimmerman Timothy M E Davis Christopher L King Pascal Michon Ivo Mueller |
| author_sort |
Anna Rosanas-Urgell |
| title |
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| title_short |
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| title_full |
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| title_fullStr |
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| title_full_unstemmed |
Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study. |
| title_sort |
reduced risk of plasmodium vivax malaria in papua new guinean children with southeast asian ovalocytosis in two cohorts and a case-control study. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2012 |
| url |
https://doaj.org/article/edb9fbd2367a41d599df991edc0a382c |
| work_keys_str_mv |
AT annarosanasurgell reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT enmoorelin reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT laurensmanning reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT patriciararau reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT moseslaman reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT nicolassenn reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT briantgrimberg reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT livingstonetavul reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT danielleistanisic reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT leannejrobinson reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT johnjaponte reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT elijahdabod reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT johncreeder reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT petersiba reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT peterazimmerman reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT timothymedavis reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT christopherlking reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT pascalmichon reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy AT ivomueller reducedriskofplasmodiumvivaxmalariainpapuanewguineanchildrenwithsoutheastasianovalocytosisintwocohortsandacasecontrolstudy |
| _version_ |
1718424826285129728 |